Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM21-1480 in Advanced Solid Tumors
NCT04442126Phase 2Terminated
- Sponsor
- Numab Therapeutics AG
- Start
- Aug 2020
- Primary completion
- Feb 2024
- Modality
- Trispecific Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of nm21-1480 in solid tumor (advanced stage), sponsored by Numab Therapeutics AG. Started Aug 2020; status: terminated.
02
Drugs
nm21-1480
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04442126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04442126.